An injectable self-adaptive polymer as a drug carrier for the treatment of nontraumatic early-stage osteonecrosis of the femoral head

Abstract

Core decompression (CD) with the elimination of osteonecrotic bone is the most common strategy for treating early-stage nontraumatic osteonecrosis of the femoral head (ONFH). Adjuvant treatments are widely used in combination with CD as suitable methods of therapy. Existing augmentations have to be fabricated in advance. Here, we report a novel injectable glycerin-modified polycaprolactone (GPCL) that can adapt to the shape of the CD cavity. GPCL shows great flowability at 52.6 °C. After solidification, its compressive modulus was 120 kPa at body temperature (37 °C). This excellent characteristic enables the polymer to provide mechanical support in vivo. In addition, GPCL acts as a carrier of the therapeutic agent zoledronic acid (ZA), demonstrating sustained release into the CD region. ZA-loaded GPCL was injected into ONFH lesions to treat early-stage nontraumatic cases. Compared to that in the CD group, CD+ZA-loaded GPCL injection preserved bone density and increased the collagen level in the femoral head. At the interface between the GPCL and CD tunnel wall, osteogenesis was significantly promoted. In addition, morphological evaluations revealed that the femoral heads in the CD+ZA-GPCL group exhibited improved pressure resistance. These results suggest a strategy effective to preserve the bone density of the femoral head, thus decreasing the possibility of femoral head collapse. This novel injectable polymer has, therefore, considerable potential in clinical applications.

References

[1] Israelite C et al. Bilateral core decompression for osteonecrosis of the femoral head. Clin. Orthop. Relat. Res., 2005, 441: 285-290

[2] Yoon BH et al. Etiologic classification criteria of ARCO on femoral head osteonecrosis part 1: glucocorticoid-associated osteonecrosis. J. Arthroplast., 2019, 34: 163-168

[3] Hungerford DS. Osteonecrosis: avoiding total hip arthroplasty. J. Arthroplast., 2002, 17: 121-124

[4] Mont MA, Salem HS, Piuzzi NS, Goodman SB, Jones LC. Nontraumatic osteonecrosis of the femoral head: where do we stand today?: a 5-year update. J. Bone Joint Surg. Am., 2020, 102: 1084-1099

[5] Zhao D et al. Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version). J. Orthop. Transl., 2020, 21: 100-110

[6] Zhang Q et al. Surgical procedures for hip joint preservation for osteonecrosis of the femoral head: a bibliometric analysis. BioMed. Res. Int., 2021, 2021: 1-14

[7] Uesugi Y et al. Quality of life of patients with osteonecrosis of the femoral head: a multicentre study. Int. Orthop., 2018, 42: 1517-1525

[8] Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J. Am. Acad. Orthop. Surg., 1999, 7: 250-261

[9] Molloy IB, Martin BI, Moschetti WE, Jevsevar DS. Effects of the length of stay on the cost of total knee and total hip arthroplasty from 2002 to 2013. J. Bone Joint Surg. Am., 2017, 99: 402-407

[10] Pollock, M., Somerville, L., Firth, A. & Lanting, B. Outpatient total hip arthroplasty, total knee arthroplasty, and unicompartmental knee arthroplasty: a systematic review of the literature. JBJS Rev. 4, e4 (2016).

[11] Swarup I et al. Implant survival and patient-reported outcomes after total hip arthroplasty in young patients. J. Arthroplast., 2018, 33: 2893-2898

[12] Cohen-Rosenblum A, Cui Q. Osteonecrosis of the femoral head. Orthop. Clin. North Am., 2019, 50: 139-149

[13] Yu X et al. Effectiveness of various hip preservation treatments for non-traumatic osteonecrosis of the femoral head: a network meta-analysis of randomized controlled trials. J. Orthop. Sci., 2018, 23: 356-364

[14] Goodman SB. The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. Int Orthop., 2018, 42: 1705-1709

[15] Andronic O, Weiss O, Shoman H, Kriechling P, Khanduja V. What are the outcomes of core decompression without augmentation in patients with nontraumatic osteonecrosis of the femoral head? Int. Orthop., 2021, 45: 605-613

[16] Marker DR, Seyler TM, Ulrich SD, Srivastava S, Mont MA. Do modern techniques improve core decompression outcomes for hip osteonecrosis? Clin. Orthop. Relat. Res., 2008, 466: 1093-1103

[17] Maruyama M et al. The effects of a functionally-graded scaffold and bone marrow-derived mononuclear cells on steroid-induced femoral head osteonecrosis. Biomaterials, 2018, 187: 39-46

[18] Zhang CQ et al. Free vascularised fibular graft for post-traumatic osteonecrosis of the femoral head in teenage patients. J. Bone Joint Surg. Br., 2011, 93: 1314-1319

[19] Veillette CJ, Mehdian H, Schemitsch EH, McKee MD. Survivorship analysis and radiographic outcome following tantalum rod insertion for osteonecrosis of the femoral head. J. Bone Joint Surg. Am., 2006, 88: 48-55

[20] Hamada H, Takao M, Sakai T, Sugano N. Subchondral fracture begins from the bone resorption area in osteonecrosis of the femoral head: a micro-computerised tomography study. Int. Orthop., 2018, 42: 1479-1484

[21] Kawano K et al. Differences in the microarchitectural features of the lateral collapsed lesion between osteonecrosis and subchondral insufficiency fracture of the femoral head. Bone, 2020, 141: 115585

[22] Baba S et al. Quantitative evaluation of bone-resorptive lesion volume in osteonecrosis of the femoral head using micro-computed tomography. Joint Bone Spine, 2020, 87: 75-80

[23] Weinstein RS. Glucocorticoid-induced bone disease. N. Engl. J. Med., 2011, 365: 62-70

[24] Mhaskar R, Djulbegovic B. Bisphosphonates for patients diagnosed with multiple myeloma. JAMA, 2018, 320: 1483-1484

[25] Singer FR. Paget disease: when to treat and when not to treat. Nat. Rev. Rheumatol., 2009, 5: 483-489

[26] Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br. J. Clin. Pharm., 2019, 85: 1052-1062

[27] Reid IR. Short-term and long-term effects of osteoporosis therapies. Nat. Rev. Endocrinol., 2015, 11: 418-428

[28] Morgan GJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 2010, 376: 1989-1999

[29] Raje N et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol., 2018, 19: 370-381

[30] Maruyama M et al. The efficacy of lapine preconditioned or genetically modified IL4 over-expressing bone marrow-derived mesenchymal stromal cells in corticosteroid-associated osteonecrosis of the femoral head in rabbits. Biomaterials, 2021, 275: 120972

[31] Yue S, He H, Li B, Hou T. Hydrogel as a biomaterial for bone tissue engineering: a review. Nanomaterials (Basel), 2020, 10: 1511

[32] Hasani-Sadrabadi MM et al. An engineered cell-laden adhesive hydrogel promotes craniofacial bone tissue regeneration in rats. Sci. Transl. Med., 2020, 12: eaay6853

[33] Benmassaoud MM, Gultian KA, DiCerbo M, Vega SL. Hydrogel screening approaches for bone and cartilage tissue regeneration. Ann. N. Y. Acad. Sci., 2020, 1460: 25-42

[34] Kondiah PJ et al. A review of injectable polymeric hydrogel systems for application in bone tissue engineering. Molecules, 2016, 21: 1580

[35] He M et al. Porous tantalum rod implantation is associated with low survival rates in patients with type C2 osteonecrosis of the femoral head but has no effect on the clinical outcome of conversion total hip arthroplasty: a retrospective study with an average 8-year follow-up. BMC Musculoskelet. Disord., 2020, 21

[36] Mondal D, Dixon SJ, Mequanint K, Rizkalla AS. Mechanically-competent and cytocompatible polycaprolactone-borophosphosilicate hybrid biomaterials. J. Mech. Behav. Biomed. Mater., 2017, 75: 180-189

[37] Ciardelli G et al. Blends of poly-(epsilon-caprolactone) and polysaccharides in tissue engineering applications. Biomacromolecules, 2005, 6: 1961-1976

[38] Camarero-Espinosa S, Moroni L. Janus 3D printed dynamic scaffolds for nanovibration-driven bone regeneration. Nat. Commun., 2021, 12

[39] Pirosa A et al. An in vitro chondro-osteo-vascular triphasic model of the osteochondral complex. Biomaterials, 2021, 272: 120773

[40] Porrelli D et al. Antibacterial electrospun polycaprolactone membranes coated with polysaccharides and silver nanoparticles for guided bone and tissue regeneration. ACS Appl. Mater. Interfaces, 2021, 13: 17255-17267

[41] Sosnoski DM, Gay CV. Evaluation of bone-derived and marrow-derived vascular endothelial cells by microarray analysis. J. Cell Biochem., 2007, 102: 463-472

[42] Thomas G et al. Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype. J. Biol. Chem., 2003, 278: 50563-50571

[43] Zhou Y et al. The methylation of Notch1 promoter mediates the osteogenesis differentiation in human aortic valve interstitial cells through Wnt/beta-catenin signaling. J. Cell Physiol., 2019, 234: 20366-20376

[44] Wang BL et al. Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch. Orthop. Trauma Surg., 2010, 130: 859-865

[45] Maruyama M et al. The efficacy of core decompression for steroid-associated osteonecrosis of the femoral head in rabbits. J. Orthop. Res., 2020, 39: 1441-1451

[46] Yang P et al. Core decompression in combination with nano-hydroxyapatite/polyamide 66 rod for the treatment of osteonecrosis of the femoral head. Arch. Orthop. Trauma Surg., 2014, 134: 103-112

[47] Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR. Nontraumatic osteonecrosis of the femoral head: where do we stand today? A ten-year update. J. Bone Joint Surg. Am., 2015, 97: 1604-1627

[48] Mont, M. A., Ragland, P. S. & Etienne, G. Core decompression of the femoral head for osteonecrosis using percutaneous multiple small-diameter drilling. Clin. Orthop. Relat. Res.131–138 (2004).

[49] Kong L et al. Repair materials for bone defects of the tibial plateau in primary total knee arthroplasty. Mater. Express, 2020, 10: 1965-1977

[50] Li X et al. Combined study on the action and mechanism of G-Rg1/Sr-CaS bone substitute material for ossification and pro-vascularization. Mater. Express, 2020, 10: 177-189

[51] Zhao D et al. Vascularized bone grafting fixed by biodegradable magnesium screw for treating osteonecrosis of the femoral head. Biomaterials, 2016, 81: 84-92

[52] Li D, Yang Z, Wei Z, Kang P. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: a PRISMA-compliant meta-analysis of animal studies and clinical trials. Sci. Rep., 2018, 8

[53] Lee YK et al. Does zoledronate prevent femoral head collapse from osteonecrosis? A prospective, randomized, open-label, multicenter study. J. Bone Joint Surg. Am., 2015, 97: 1142-1148

[54] Friedl G et al. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J. Bone Joint Surg. Am., 2009, 91: 274-281

[55] Ramasamy SK et al. Blood flow controls bone vascular function and osteogenesis. Nat. Commun., 2016, 7

[56] Wu Y et al. Role of hydrogels in bone tissue engineering: how properties shape regeneration. J. Biomed. Nanotechnol., 2020, 16: 1667-1686

[57] Zhang X et al. Hyperbranched polymer micelles with triple-stimuli backbone-breakable iminoboronate ester linkages. Chin. Chem. Lett., 2020, 31: 1822-1826

[58] Yang W et al. Fibrin scaffolds embedded with sonic hedgehog/chitosan microspheres for recovery of spinal cord injury in rats. Mater. Express, 2020, 10: 437-445

[59] Huang K, Liu G, Gu Z, Wu J. Tofu as excellent scaffolds for potential bone regeneration. Chin. Chem. Lett., 2020, 31: 3190-3194

[60] Zhao D, Ma Z. Application of biomaterials for the repair and treatment of osteonecrosis of the femoral head. Regen. Biomater., 2020, 7: 1-8

[61] Lu X et al. Nanoparticle shaped titanium promotes osteogenic differentiation of bone mesenchymal stem cells through integrin/integrin linked kinase/glycogen synthase kinase-3β axis. J. Biomed. Nanotechnol., 2020, 16: 1267-1275

[62] Little DG et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J. Bone Min. Res., 2003, 18: 1300-1307

[63] Zwolak P, Farei-Campagna J, Jentzsch T, von Rechenberg B, Werner CM. Local effect of zoledronic acid on new bone formation in posterolateral spinal fusion with demineralized bone matrix in a murine model. Arch. Orthop. Trauma Surg., 2018, 138: 13-18

[64] Bilston LE, Little DG, Smith NC, Williams P, Briody J. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin. Biomech. (Bristol, Avon), 2002, 17: 716-718

[65] Hughes R et al. Bone marrow osteoprogenitors are depleted whereas osteoblasts are expanded independent of the osteogenic vasculature in response to zoledronic acid. FASEB J., 2019, 33: 12768-12779

[66] Marofi F et al. Epigenetic mechanisms are behind the regulation of the key genes associated with the osteoblastic differentiation of the mesenchymal stem cells: the role of zoledronic acid on tuning the epigenetic changes. J. Cell Physiol., 2019, 234: 15108-15122

[67] Qin L et al. Multiple bioimaging modalities in evaluation of an experimental osteonecrosis induced by a combination of lipopolysaccharide and methylprednisolone. Bone, 2006, 39: 863-871

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81672173)

Key Research Development Program of Shaanxi Province, 2018ZDCXL-SF-28-7